Abpro Holdings, Inc. and Celltrion have announced a strategic partnership for the global development of ABP-102/CT-P72, a bispecific T-cell engager designed to target HER2-positive cancers, which ...
Data suggest potential for superior tumor selectivity, potent efficacy, and improved safety profile Abpro and Celltrion have a strategic partnership for worldwide development and commercialization of ...
ABP-102/CT-P72 represents Abpro’s first IND submission for a phase 1 trial in a solid tumor indication, and is being co-developed by Abpro and Celltrion, Inc. BURLINGTON, Mass., Dec. 15, 2025 (GLOBE ...
BURLINGTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq: ABP), a clinical-stage biotechnology company developing next-generation antibody therapeutics for solid tumors, today ...
Abpro, an integrated life science company at the forefront of synthetic biology, today announced a partnership with Essex Bio, a China-based biopharmaceutical company. Abpro and Essex will co-develop ...
Abpro is taking a second run at the public markets. Five years after pulling out of a planned IPO, the antibody specialist is back with a special purpose acquisition company, agreeing to combine with ...
Abpro Holdings, Inc., a biotechnology company focused on developing antibody therapies for severe diseases, has announced the departure of CEO Ian Chan. Miles Suk, the Board Chairman, expressed ...
WOBURN, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Abpro Corporation, a clinical stage biotechnology company developing next-generation antibody therapies, today shared an assessment of its neutralizing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results